ribociclib
novartis
['mbc', 'ribociclib']
maintain randomized phase ii trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cdk 4/6i in hr+her2- mbc presented by k kalinsky #asco22 #oncoalert 
Associate Professor, Florence University, Italy. Clinical Oncologist with focus on breast, radiation, research. Opinions are my own. RT not endorsement.